THANK YOU FOR SUBSCRIBING
The FDA approves Endomag's latest breast cancer treatment for women worldwide.
FREMONT, CA: “This much-anticipated approval allows any surgeon, regardless of hospital setting, to offer their patients the best standard of treatment in breast cancer staging. For the first time in the U.S., operating departments will not have to rely on Nuclear Medicine before they can operate on their patients,” says Dr. Eric Mayes, Endomag CEO. Endomag is delighted to reveal that the Magtrace® lymphatic tracer can now be utilized for all patients having breast cancer surgery. This development will revolutionize breast cancer staging in the United States and reduce reliance on radioactive tracers with unpredictable availability.
"From the many conversations we have every day with surgeons across the U.S., we know they're so excited about what this means for improving efficiencies and the patient experience,” add Mayes.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Magtrace is the first tracer built exclusively to optimize the Sentinel Lymph Node Biopsy method for breast cancer staging. It helps surgeons assess if the tumor has progressed beyond the breast by identifying the first draining lymph nodes in the armpit for further examination.
One of the main advantages of Magtrace over the existing practice of utilizing a radioactive tracer combination is that nuclear medicine supply chain concerns do not constrain it. This eliminates the need for hospitals to postpone or cancel procedures for cancer patients.
"In the past month, there have been a lot of breast cancer patients across the U.S. who have had their surgery delayed due to the ongoing shortages of Technetium-99. Fortunately, we were the first site in the U.S. to adopt Magtrace several years ago, and we've been able to completely avoid these issues," says Michael Alvarado, MD, Professor of Surgery at UCSF. "What originally drew me to Magtrace were the huge benefits it could provide to our patients, including eliminating the pain of radioactive injection and reducing unnecessary surgery. I truly believe that with this news, there is no reason it shouldn't become the new standard of care for sentinel lymph node biopsy."
More in News